Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KDM1A | O60341 | 3/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1707562 | 0.94 | POLB (0.68) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL10598558 | 0.93 | POLB (0.69) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL3784570 | 0.90 | ROCK2 (0.66) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL4688381 | 0.87 | POLB (0.62) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL8726155 | 0.86 | POLB (0.61) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL31043626 | 0.86 | POLB (0.61) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL19682897 | 0.84 | POLB (0.62) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL17356353 | 0.84 | SMN1; SMN2 (0.51) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL3942525 | 0.84 | POLB (0.66) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL22700779 | 0.83 | RAB9A (0.50) | POLBMAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0902018-B1 | 2-(Arylphenyl)amino-imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-7141584-B2 | guanidine derivatives containing phenyl and imidazole rings; useful for treating pain conditions from a wide variety of causes such as cancer, trauma, surgery, inflammation etc. | ROCHE PALO ALTO LLC (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040122053-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | BLEY KEITH ROGER (US) | 2004-06-24 | — | — | US | disclosed |
| US-6693200-B2 | IP RECEPTOR ANTAGONISTS; ANTIINFLAMMATORIES AND ANALGESICS | SYNTEX (U.S.A.) LLC | 2004-02-17 | — | — | US | disclosed |
| US-20030229123-A1 | Antiinflammatory agents; antiallergens; lipoxygenase or phospholipase inhibitors | BLEY KEITH ROGER (US) | 2003-12-11 | — | — | US | disclosed |
| US-6596876-B2 | Prostaglandin I2 inhibitors | SYNTEX (U.S.A.) LLC | 2003-07-22 | — | — | US | disclosed |
| CN-1110484-C | 2-(arylphenyl) amino-imidazoline derivatives | HOFMMANN LA ROCHE AG F (CH) | 2003-06-04 | — | — | CN | disclosed |
| US-20030036655-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | BLEY KEITH ROGER (US) | 2003-02-20 | — | — | US | disclosed |
| US-6472536-B1 | SUCH AS 2-(4-(4-CYCLOPENTYLOXYBENZYL)PHENYL)AMINO-IMIDAZOLINE; ANTINOCICEPTIVE AGENTS; IP RECEPTOR ANTAGONISTS; TREATING INFLAMMATORY PAIN | SYNTEX (U.S.A.) LLC | 2002-10-29 | — | — | US | disclosed |
| US-6184242-B1 | 2-(substituted-phenyl)amino-imidazoline derivatives | SYNTEX USA (LLC) | 2001-02-06 | — | — | US | disclosed |
| CN-1216762-A | 2-(arylphenyl) amino-imidazoline derivatives | HOFMMANN LA ROCHE AG F (CH) | 1999-05-19 | — | — | CN | disclosed |
| EP-0902018-A2 | 2-(Arylphenyl)amino-imidazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229123-A1 | Antiinflammatory agents; antiallergens; lipoxygenase or phospholipase inhibitors | LTB4R2, LTB4R, ALOX5 | POLB 3165/4885TP53 4361/4885MAPT 4794/4885 |
| US-20040122053-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | GIPR, GRK2, TBXA2R | POLB 4758/4885TP53 2368/4885MAPT 4533/4885 |
| US-20030036655-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | GIPR, TBXA2R, GRK2 | POLB 4738/4885TP53 2731/4885MAPT 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.